产业基地启航!北大分子医学南京转化研究院产业发展基地正式启用 - 园区要闻 - 南京生物医药谷 (njbpv.cn)
View attachment 172955
19-10-2021
HopeMedicine is an innovative biopharmaceutical company based on Professor Xiao Ruiping and his team from the School of Future Technology of Peking University, based on decades of research results in the field of translational medicine. At present, the company has completed the B round of financing, signed a global exclusive license agreement with Bayer for the development and industrialization of the monoclonal antibody
HMI-115 targeting the prolactin receptor (PRLR), and is developing and industrializing multiple indications worldwide change.
This antibody has the function of promoting hair growth and has a therapeutic effect on hair loss. It has shown excellent characteristics in animal models and human safety, and has obtained the approval of the US FDA Phase II clinical trial. In the near future, the US Phase II clinical trial will be launched. The patient was enrolled. In addition, Herqirui has also carried out the R&D and industrialization of more high-end innovative drugs through the dual-drive model of license-in (authorized introduction) and independent research and development.
--
SOOOO they will start Phase II clinical trial for HMI-115(hair growth) now in the US